Abstract
The MERIT study was a single-arm, phase II clinical trial of nivolumab for the second- or third-line treatment of patients with malignant pleural mesothelioma in Japan. MERIT confirmed that PD-1 inhibition has activity in mesothelioma and led to the regulatory approval of nivolumab for the treatment of mesothelioma in Japan.
Original language | English (US) |
---|---|
Pages (from-to) | 5438-5440 |
Number of pages | 3 |
Journal | Clinical Cancer Research |
Volume | 25 |
Issue number | 18 |
DOIs | |
State | Published - Sep 15 2019 |
ASJC Scopus subject areas
- Oncology
- Cancer Research